MPN

Myelofibrosis-related anemia is different than anemia experienced by patients without a cancer diagnosis, a research nurse explained.

Nurse practitioner Charina Toste explains why it is important for patients to be empowered to have educated conversation with their care teams.

Reporting MPN side effects to the care team, regardless of how “little” they may seem, can help determine how to adjust treatment to address these symptoms, an expert said.

We took a look back at the most noteworthy and compelling myeloprolifearative neoplasm stories from 2023.

Patients with MPNs can potentially experience long asymptomatic periods, and it’s up to patients and providers to remain vigilant as they monitor and manage symptoms.

This particular designation may expedite the process of approving Xpovio for the treatment of patients with myelofibrosis to address an unmet medical need.

Disease symptoms, as well as other health conditions, can have a major impact on the treatment plan for patients with myeloproliferative neoplasms.

Jaktinib significantly improved spleen volume reduction rates compared with hydroxyurea in intermediate- to high-risk myelofibrosis.

Watch Dr. Jerry Spivak, from Johns Hopkins University School of Medicine, discuss what is on the horizon in the management of polycythemia vera during the CURE® Educated Patient® MPN Summit.

Watch Dr. Nikolai Podoltsev, from Yale School of Medicine, discuss the current management of polycythemia vera during the CURE® Educated Patient® MPN Summit.

Watch Dr. Lucia Masarova, Dr. Laura C. Michaelis and Celia Militz answer questions about essential thrombocythemia during the CURE® Educated Patient® MPN Summit.

Watch Dr. Laura C. Michaelis, from the Medical College of Wisconsin, discuss the current and future management of essential thrombocythemia during the CURE® Educated Patient® MPN Summit.

Jakafi led to improved symptom score and spleen volume reductions in patients with myelofibrosis, regardless of anemia or transfusion status, recent research showed.

Watch Dr. Lucia Masarova, from MD Anderson Cancer Center, discuss risk stratifying patients with essential thrombocythemia during the CURE® Educated Patient® MPN Summit.

Because MPNs can cause chronic disease that spans years or even decades, some patients need their significant other to become their caregiver.

Patients and their caregivers may benefit from community support and education following an MPN diagnosis

Treatments with JAK inhibitors are continuing to make their way into the MPN space, providing symptom relief, but not yet a cure.

Patients with MPNs should consult with their treating physician to individualize a healthy, nutritious diet to help ease symptoms.

Researchers may have uncovered new ways to help patients with accelerated-phase and blast-phase MPNs live longer by borrowing therapies from other blood cancers.

Some symptoms of myeloproliferative neoplasms are “pretty broad,” highlighting the importance of open communication with cancer teams to manage the symptoms and improve quality of life.

Two years after receiving FDA approval, Besremi is a preferred treatment option in the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology.

A clinical trial studying an accelerated dose of Besremi recently kicked off.

Mayra Andujar Delgado does not shy away from discussing her myelofibrosis diagnosis. In fact, the survivor becomes empowered by sharing her knowledge with others.

Earlier treatment with Jakafi showed promise in both improving survival and symptom burden in certain patients with myelofibrosis, though physicians often delay Jakafi treatment.

If approved by the FDA later this year, momelotinib could fulfill an area of unmet need for patients with myelofibrosis, according to an expert.